world cancer report - iarc

worthy is the development of caspase
inhibitors for the treatment of certain
degenerative (non-cancerous) diseases
characterized by excess apoptosis.
Drugs shown to induce apoptosis specifically
include chemopreventive agents
(Chemoprevention, p151), exemplified by
REFERENCES
1. Strasser A, O'Connor L, Dixit VM (2000) Apoptosis signaling.
Annu Rev Biochem, 69: 217-245.
2. Kaufmann SH, Gores GJ (2000) Apoptosis in cancer:
cause and cure. Bioessays, 22: 1007-1017.
3. Parton M, Dowsett M, Smith I (2001) Studies of apoptosis
in breast cancer. BMJ, 322: 1528-1532.
4. Choisy-Rossi C, Yonish-Rouach E (1998) Apoptosis and
the cell cycle: the p53 connection. Cell Death Differ, 5:
129-131.
5. Rich T, Allen RL, Wyllie AH (2000) Defying death after
DNA damage. Nature, 407: 777-783.
6. Peter ME, Krammer PH (1998) Mechanisms of CD95
(APO-1/Fas)-mediated apoptosis. Curr Opin Immunol, 10:
545-551.
7. Yeh WC, Hakem R, Woo M, Mak TW (1999) Gene targeting
in the analysis of mammalian apoptosis and TNF
receptor superfamily signaling. Immunol Rev, 169: 283-
302.
8. Griffith TS, Lynch DH (1998) TRAIL: a molecule with
multiple receptors and control mechanisms. Curr Opin
Immunol, 10: 559-563.
9. Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2
family members and the mitochondria in apoptosis. Genes
Dev, 13: 1899-1911.
10. Matsuyama S, Llopis J, Deveraux QL, Tsien RY, Reed
JC (2000) Changes in intramitochondrial and cytosolic pH:
118 Mechanisms of tumour development
4-hydroxyphenylretinamide. Butyrate, a
short-chain fatty acid produced by bacterial
fermentation of dietary fibre, inhibits
cell growth in vitro and promotes differentiation;
it also induces apoptosis. Both
roles may contribute to its prevention of
colorectal cancer. Moreover, cyclo-oxyge-
early events that modulate caspase activation during apoptosis.
Nat Cell Biol, 2: 318-325.
11. Chung HT, Pae HO, Choi BM, Billiar TR, Kim YM (2001)
Nitric oxide as a bioregulator of apoptosis. Biochem
Biophys Res Commun, 282: 1075-1079.
12. Kumar S (1999) Regulation of caspase activation in
apoptosis: implications in pathogenesis and treatment of
disease. Clin Exp Pharmacol Physiol, 26: 295-303.
13. Porter AG, Janicke RU (1999) Emerging roles of caspase-3
in apoptosis. Cell Death Differ, 6: 99-104.
14. Nicholson DW (2000) From bench to clinic with apoptosis-based
therapeutic agents. Nature, 407: 810-816.
15. Zhou BB, Elledge SJ (2000) The DNA damage
response: putting checkpoints in perspective. Nature, 408:
433-439.
16. Brown JM, Wouters BG (1999) Apoptosis, p53, and
tumor cell sensitivity to anticancer agents. Cancer Res, 59:
1391-1399.
17. Zheng TS (2001) Death by design: the big debut of
small molecules. Nat Cell Biol, 3: E43-E46.
18. Altucci L, Rossin A, Raffelsberger W, Reitmair A,
Chomienne C, Gronemeyer H (2001) Retinoic acid-induced
apoptosis in leukemia cells is mediated by paracrine action
of tumor-selective death ligand TRAIL. Nat Med, 7: 680-
686.
nase enzyme (COX-2) expression may
modulate intestinal apoptosis via changes
in Bcl-2 expression. Aspirin and similar
drugs which inhibit COX-2 may promote
apoptosis and prevent tumour formation.
WEBSITE
The European Cell Death Organization:
http://www.ecdo.dote.hu/